01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
19:10 , Mar 17, 2017 |  BC Week In Review  |  Company News

Regen, CheckPoint deal

Regen granted its CheckPoint Immunology Inc. subsidiary an exclusive, worldwide license to develop and commercialize nuclear receptor subfamily 2 group F member 6 ( NR2F6 ; COUP-TFIII) technology for human therapeutic use. The subsidiary plans...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Eli Lilly, Regen BioPharma deal

Regen and Eli Lilly partnered to evaluate Lilly compounds with Regen’s nuclear receptor subfamily 2 group F member 6 ( NR2F6 ; COUP-TFIII ) high throughput screening program. Regen will screen 21,000 compounds from Lilly...
07:00 , Oct 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 2 group F member 6 (NR2F6; COUP-TFIII)

Cancer INDICATION: Cancer Mouse studies suggest inhibiting NR2F6 could help treat cancer. In a transgenic mouse model of prostate cancer, NR2F6 knockout increased tumor infiltration by CD4+ and CD8+ T cells expressing interleukin-2 (IL-2) or...